Investors Bet Big on Oric Pharmaceuticals Call Options

Surge in options trading activity signals bullish sentiment on biotech stock

Apr. 2, 2026 at 2:34pm

Got story updates? Submit your updates here. ›

Oric Pharmaceuticals (NASDAQ:ORIC) saw a significant increase in call option trading activity on Thursday, with traders purchasing 2,266 call options - a 2,058% jump from the typical daily volume of 105 call options. This unusual options activity suggests investors are betting on potential upside for the biotech company's stock.

Why it matters

The spike in call option trading for Oric Pharmaceuticals could indicate that investors are anticipating positive news or developments for the company, which is focused on developing small molecule therapeutics to overcome resistance mechanisms in solid tumor oncology. Options activity can provide insights into market sentiment and expectations around a stock.

The details

Oric Pharmaceuticals is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The company's lead candidate, ORIC-101, is a selective, orally available antagonist of the glucocorticoid receptor currently being evaluated in Phase 1/2 trials for patients with solid tumors who have acquired resistance to chemotherapy and hormonal agents.

  • The unusual options activity was observed on Thursday, April 2, 2026.

The players

Oric Pharmaceuticals, Inc.

A clinical-stage biopharmaceutical company focused on developing small molecule therapeutics to overcome resistance mechanisms in solid tumor oncology.

Got photos? Submit your photos here. ›

What’s next

Investors will be closely watching for any updates or developments related to Oric Pharmaceuticals' clinical trials and pipeline progress, as these could impact the stock price and options activity.

The takeaway

The surge in call option trading for Oric Pharmaceuticals suggests that investors are bullish on the company's prospects, despite some recent concerns around safety signals and optimal dosing. This options activity provides a glimpse into market sentiment and expectations around the biotech firm's future performance.